Nuvectis Pharma (NVCT) Competitors

Nuvectis Pharma (NASDAQ:NVCT) and Cronos Group (NASDAQ:CRON) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, dividends, profitability, community ranking, risk, analyst recommendations, valuation, earnings and institutional ownership.

Does the media favor NVCT or CRON?

In the previous week, Cronos Group had 3 more articles in the media than Nuvectis Pharma. MarketBeat recorded 4 mentions for Cronos Group and 1 mentions for Nuvectis Pharma. Cronos Group's average media sentiment score of 1.16 beat Nuvectis Pharma's score of 0.96 indicating that Cronos Group is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nuvectis Pharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cronos Group	2 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Is NVCT or CRON more profitable?

Nuvectis Pharma has a net margin of 0.00% compared to Cronos Group's net margin of -42.65%. Cronos Group's return on equity of -2.56% beat Nuvectis Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nuvectis Pharma	N/A	-155.80%	-104.02%
Cronos Group	-42.65%	-2.56%	-2.47%

Do analysts prefer NVCT or CRON?

Nuvectis Pharma presently has a consensus target price of $17.00, suggesting a potential upside of 69.15%. Given Nuvectis Pharma's stronger consensus rating and higher probable upside, equities analysts plainly believe Nuvectis Pharma is more favorable than Cronos Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nuvectis Pharma	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00
Cronos Group	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Which has more volatility & risk, NVCT or CRON?

Nuvectis Pharma has a beta of -0.11, suggesting that its share price is 111% less volatile than the S&P 500. Comparatively, Cronos Group has a beta of 1.06, suggesting that its share price is 6% more volatile than the S&P 500.

Do institutionals & insiders have more ownership in NVCT or CRON?

96.8% of Nuvectis Pharma shares are owned by institutional investors. Comparatively, 8.7% of Cronos Group shares are owned by institutional investors. 35.8% of Nuvectis Pharma shares are owned by company insiders. Comparatively, 7.3% of Cronos Group shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Does the MarketBeat Community prefer NVCT or CRON?

Cronos Group received 451 more outperform votes than Nuvectis Pharma when rated by MarketBeat users. However, 92.86% of users gave Nuvectis Pharma an outperform vote while only 61.13% of users gave Cronos Group an outperform vote.

Company	Underperform	Outperform
Nuvectis Pharma	Outperform Votes 13 92.86%	Underperform Votes 1 7.14%
Cronos Group	Outperform Votes 464 61.13%	Underperform Votes 295 38.87%

Which has preferable valuation and earnings, NVCT or CRON?

Nuvectis Pharma has higher earnings, but lower revenue than Cronos Group. Nuvectis Pharma is trading at a lower price-to-earnings ratio than Cronos Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nuvectis Pharma	N/A	N/A	-$22.26M	-$1.13	-8.89
Cronos Group	$124.59M	6.40	-$73.96M	$0.13	15.92

Summary

Nuvectis Pharma beats Cronos Group on 9 of the 17 factors compared between the two stocks.